{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:43:49Z","timestamp":1794573829710,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.pharmthera.2025.108811","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:55:40Z","timestamp":1739188540000},"page":"108811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?"],"prefix":"10.1016","volume":"268","author":[{"given":"Konstantinos","family":"Arvanitakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Germanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2025.108811_bb0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0037-1601350","article-title":"Inflammasomes in liver fibrosis","volume":"37","author":"Alegre","year":"2017","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13543784.2020.1708899","article-title":"Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: Rationale for the development of resmetirom (MGL-3196)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102935","article-title":"Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential","volume":"18","author":"Arvanitakis","year":"2024","journal-title":"Diabetes and Metabolic Syndrome: Clinical Research and Reviews"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106261","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications","volume":"181","author":"Arvanitakis","year":"2022","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0030","series-title":"How far beyond diabetes can the benefits of glucagon-like Peptide-1 receptor agonists go?","first-page":"14","author":"Arvanitakis","year":"2022"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914704","article-title":"Meeting at the crossroad between obesity and hepatic carcinogenesis: Unique pathophysiological pathways raise expectations for innovative therapeutic approaches","volume":"24","author":"Arvanitakis","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0055","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2021.100111","article-title":"Racial\/ethnic and socioeconomic disparities in the use of newer diabetes medications in the look AHEAD study","volume":"6","author":"Elhussein","year":"2022","journal-title":"The Lancet Regional Health \u2013 Americas"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2023.01.010","article-title":"Future treatment options and regimens for nonalcoholic fatty liver disease","volume":"27","author":"Francque","year":"2023","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0070","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0075","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0080","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled Trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0095","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","article-title":"Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: An analysis of data from a prospective cohort study","volume":"9","author":"Israelsen","year":"2024","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s41669-022-00370-2","article-title":"Early cost-effectiveness and Price threshold analyses of Resmetirom: An investigational treatment for Management of Nonalcoholic Steatohepatitis","volume":"7","author":"Javanbakht","year":"2023","journal-title":"PharmacoEconomics - Open"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: An orally administered, Smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"touchREV Endocrinol"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-lancet liver commission: Protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0120","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1521\u20131530","key":"10.1016\/j.pharmthera.2025.108811_bb0125","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0130","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: Pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14656566.2024.2312239","article-title":"Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: Not yet ready for prime time!","volume":"25","author":"Koufakis","year":"2024","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103034","article-title":"Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom","volume":"18","author":"Kuchay","year":"2024","journal-title":"Diabetes and Metabolic Syndrome: Clinical Research and Reviews"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0145","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clinical and Molecular Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: A Nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"European Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155935","article-title":"Resmetirom for MASH patients with diabetes: Challenges and opportunities in the real world","volume":"156","author":"Lian","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0165","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3389\/fimmu.2018.02201","article-title":"Inflammasome: A double-edged sword in liver diseases","volume":"9","author":"Luan","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0170","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/HEP.0000000000000551","article-title":"Thyroid hormone action and liver disease, a complex interplay","volume":"81","author":"Marino","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0175","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0180","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert panel recommendations: Practical clinical applications for initiating and monitoring Resmetirom in patients with MASH\/NASH and moderate to noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0185","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41575-024-00955-8","article-title":"in MASH-related compensated cirrhosis","volume":"21","author":"Pericas","year":"2024","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"1147\u20131159","key":"10.1016\/j.pharmthera.2025.108811_bb0190","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0195","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0200","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","article-title":"Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis","volume":"386","author":"Richeldi","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0205","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metabolism"},{"issue":"377\u2013384","key":"10.1016\/j.pharmthera.2025.108811_bb0215","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0220","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0225","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0230","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2014.07.001","article-title":"Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism","volume":"25","author":"Sinha","year":"2014","journal-title":"Trends in Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0240","series-title":"Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report","author":"Tice","year":"2023"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi0759","article-title":"Found in translation-fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)","volume":"15","author":"Wang","year":"2023","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0250","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis","author":"Younossi","year":"2024","journal-title":"Hepatology"},{"issue":"1354\u20131361","key":"10.1016\/j.pharmthera.2025.108811_bb0255","article-title":"Hepatic fat reduction due to Resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0260","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2025.108811_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nm.4447","article-title":"Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function","volume":"24","author":"Yu","year":"2018","journal-title":"Nature Medicine"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:57:44Z","timestamp":1741082264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"alternative-id":["S0163725825000233"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108811","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108811"}}